Investigating Dupilumab's Effect in Asthma by Genotype

Eligibility Criteria

• 1. Ages 12 years and older
• 2. Ability to provide informed consent
• 3. Ability to perform pulmonary function tests
• 4. Female participants of childbearing potential must have a negative urine pregnancy test upon study entry
• 5. Female participants with reproductive potential must agree to use FDA-approved methods of birth control for the duration of the study2
• 6. Participant-reported physician or licensed medical practitioner diagnosis of asthma
• 7. Treatment with medium to high dose ICS (400 mcg to maximum of 2000 mcg per day of fluticasone propionate or equivalent) for at least 3 months with a stable dose ≥1 month prior to screening OR used a biologic medication for asthma within the past 8 weeks
• 8. History of asthma exacerbation in the past year
• 1. Chronic lung disease other than asthma, which may impair lung function
• 2. Current smoker or cessation of smoking ≤6 months prior to Visit 0 screening
• 3. Current use of any electronic (e) "vaping" device (e.g., e-cigarette, e-cig, mod, vape pen, JUUL, e-cigar, e-hookah, e-pipe, vape pods) or cessation ≤ 6 months prior to screening
• 4. Pregnant or breast feeding
• 5. Any other condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the patient or quality of data
• 6. Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures
• 7. Planning to relocate away from the clinical center area before study completion
• 8. Currently participating in an investigational drug trial or participated in one within 30 days before screening
• 9. Currently being treated with immunosuppressive/immunomodulatory or other investigational agents or biologics for conditions other than asthma, or used a biologic for a non-asthma indication within the past 6 months
• 10. History of respiratory illness requiring antibiotics or systemic corticosteroids, including asthma exacerbations, within the past 4 weeks (evaluated at time of screening visit)
• 11. History of alcohol or illicit substance abuse within 6 months of screening
• 12. Neutropenia (\<1,000/mm3) or thrombocytopenia (\<100,000/mm3) or hemoglobin \< 100 g/L (10 g/dL) or blood eosinophils \> 1500/mm3 at screening
• 13. Administration of a live vaccine within 4 weeks of screening
• 14. Currently receiving allergen immunotherapy (food or aeroallergen) other than an established maintenance regimen implemented continuously for a minimum of 2 months. Individuals receiving aeroallergen immunotherapy must be willing to stay on it for the duration of the study.